JMS Co

JMS Co Long-term Debt

The Long-Term Debt of JMS Co (7702.T) as of Nov 2, 2026 is 12.01 B JPY. In the previous year, Long-Term Debt was 11.79 B JPY — a change of 1.80% (higher).

Long-term Debt

12.01 BJPY

YoY

1.80%

Last updated:

Long-Term Debt of JMS Co is 2026 12.01 B JPY. Long-Term Debt of JMS Co was 2025 11.79 B JPY. It decreases by 1.80% higher compared to the previous year.

The JMS Co Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2019
10.63 B JPY
Jan 1, 2020
9.99 B JPY
Jan 1, 2021
9.83 B JPY
Jan 1, 2022
10.36 B JPY
Jan 1, 2023
11.66 B JPY
Jan 1, 2024
11.07 B JPY
Jan 1, 2025
11.79 B JPY
Jan 1, 2026
12.01 B JPY
The JMS Co Long-term Debt history
YEARLong-term DebtYoY
12.01 BJPY+1.80%
11.79 BJPY+6.56%
11.07 BJPY-5.07%
11.66 BJPY+12.49%
10.36 BJPY+5.42%
9.83 BJPY-1.55%
9.99 BJPY-6.02%
10.63 BJPY-11.15%
11.96 BJPY+2.70%
11.65 BJPY+11.36%
10.46 BJPY+64.06%
6.37 BJPY+142.17%
2.63 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JMS Co Stock analysis

What does JMS Co do? JMS Co., Ltd. generates revenue through the manufacture, sale, export, and import of medical devices and pharmaceuticals across its five geographical segments: Japan, Singapore, China, Philippines, and Germany. The company offers a range of products including infusion and nutrition products, dialysis products, surgery products, blood and cell products, and other related items. Key products such as infusion & transfusion sets, syringe pumps, surgical gowns, dialysis kits, peritoneal dialysate, microcatheters, and blood bags are sold to healthcare providers and institutions within these regions. The firm also provides maintenance services and other related services as part of its product portfolio. The company's primary customers are healthcare providers and institutions in Japan, Singapore, China, Philippines, and Germany, where it operates through its five geographical segments. These customers purchase medical equipment and drugs, including specific items like infusion & transfusion sets, dialysis kits, and surgical gowns. The firm's product lines are tailored to meet the needs of hospitals, clinics, and other medical facilities across its operational regions. JMS Co., Ltd. focuses on manufacturing and selling medical equipment and drugs, with a strong emphasis on products such as infusion & transfusion sets, syringe pumps, surgical gowns, and dialysis kits. The company's revenue streams are driven by the sale of these products and the provision of maintenance services. Its geographical segments ensure a diversified market presence, allowing it to serve various healthcare sectors in different countries. JMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JMS Co stock

Long-Term Debt of JMS Co is 12.01 B JPY in 2026.

Long-Term Debt of JMS Co changed from 11.79 B JPY to 12.01 B JPY, representing a 1.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt JMS Co since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's JMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — JMS Co

All Key Metrics — JMS Co